Elevated serum IL-34 is correlated with disease severity in patients with biliary atresia following Kasai portoenterostomy

dc.contributor.authorHonsawek S.
dc.contributor.authorBovornsethanant N.
dc.contributor.authorWoraruthai T.
dc.contributor.authorVejchapipat P.
dc.contributor.authorUdomsinprasert W.
dc.contributor.authorPoovorawan Y.
dc.contributor.correspondenceHonsawek S.
dc.contributor.otherMahidol University
dc.date.accessioned2024-02-08T18:18:48Z
dc.date.available2024-02-08T18:18:48Z
dc.date.issued2024-01-25
dc.description.abstractBackground: Biliary atresia (BA) is a severe congenital disorder with progressive obstructive cholangiopathy in young children. The inflammatory process has been recognized as one of the pathological mechanisms driving bile duct injury. Since interleukin-34 (IL-34) has been reportedly linked to several pathological liver disorders, including inflammation, the current study aimed to analyze circulating IL-34 and the association of circulating IL-34 with hepatic deterioration and clinical outcomes in post-Kasai BA children. Methods: Circulating IL-34 levels were analyzed in 89 post-Kasai BA subjects and 45 healthy individuals using an ELISA. Liver stiffness (hardness) was measured by ultrasound elastography. Results: Circulating IL-34 was substantially higher in BA children than in control individuals, particularly those with unfavorable outcomes including hepatic dysfunction, jaundice, and portal hypertension. In BA group, circulating IL-34 was positively correlated with liver stiffness (r = 0.515, p < 0.001), AST (r = 0.403, p < 0.001), ALT (r = 0.279, p = 0.008), total bilirubin (r = 0.224, p = 0.03), ALP (r = 0.255, p = 0.016), and serum IL-6 (r = 0.590, p < 0.001) but inversely correlated with albumin (r = -0.417, p < 0.001). Kaplan-Meier survival analysis showed that higher circulating IL-34 levels were significantly associated with reduced survival rates in BA subjects (p = 0.002). Conclusion: Higher circulating IL-34 values were directly associated with hepatic impairment and the BA severity, implicating that serum IL-34 could be applied as a noninvasive marker for the monitoring of the severity in BA subjects following Kasai portoenterostomy and therapeutic efficacy.
dc.identifier.citationInternational Immunopharmacology Vol.127 (2024)
dc.identifier.doi10.1016/j.intimp.2023.111356
dc.identifier.eissn18781705
dc.identifier.issn15675769
dc.identifier.pmid38103407
dc.identifier.scopus2-s2.0-85180115024
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/95950
dc.rights.holderSCOPUS
dc.subjectPharmacology, Toxicology and Pharmaceutics
dc.subjectMedicine
dc.subjectImmunology and Microbiology
dc.titleElevated serum IL-34 is correlated with disease severity in patients with biliary atresia following Kasai portoenterostomy
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85180115024&origin=inward
oaire.citation.titleInternational Immunopharmacology
oaire.citation.volume127
oairecerif.author.affiliationMahidol University
oairecerif.author.affiliationFaculty of Medicine, Chulalongkorn University

Files

Collections